Cargando…
Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy
Mucopolysaccharidosis type IVA (MPSIVA) or Morquio A disease, a lysosomal storage disorder, is caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) deficiency, resulting in keratan sulfate (KS) and chondroitin-6-sulfate accumulation. Patients develop severe skeletal dysplasia, early cartilage...
Autores principales: | Bertolin, Joan, Sánchez, Víctor, Ribera, Albert, Jaén, Maria Luisa, Garcia, Miquel, Pujol, Anna, Sánchez, Xavier, Muñoz, Sergio, Marcó, Sara, Pérez, Jennifer, Elias, Gemma, León, Xavier, Roca, Carles, Jimenez, Veronica, Otaegui, Pedro, Mulero, Francisca, Navarro, Marc, Ruberte, Jesús, Bosch, Fatima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429698/ https://www.ncbi.nlm.nih.gov/pubmed/34504088 http://dx.doi.org/10.1038/s41467-021-25697-y |
Ejemplares similares
-
Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC
por: Marcó, Sara, et al.
Publicado: (2016) -
Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model
por: Sawamoto, Kazuki, et al.
Publicado: (2020) -
Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
por: Hendriksz, Christian J., et al.
Publicado: (2012) -
Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal
por: Marcó, Sara, et al.
Publicado: (2021) -
Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)